NASDAQ: LNTH

Lantheus (LNTH) Stock Analysis & Forecast

Nov 13 close

$101.59+0.34 (+0.3%)

Gekko Brief

AI summaryNov 9 close

Lantheus moves this week on a cluster of corporate news. The company reported third-quarter 2026 results, with worldwide revenue up 1.5% to $389.9 million and earnings beating estimates by $0.42, EPS of $1.68 against a projected $1.26. Alongside results, Lantheus detailed a definitive agreement to merge with Curium in an all-cash transaction valued at up to approximately $8.0 billion, announced FDA approvals for TAUKLARIFY and BRAVNETSA, and welcomed the CMS Calendar Year 2027 final rule preserving separate payment for diagnostic radiopharmaceuticals and extending Transitional Pass-Through status for PYLARIFY TruVu through September 30, 2029. Separately, PharmaLogic Holdings Corp. agreed to acquire Lantheus' CDMO business and its Springfield, New Jersey manufacturing facility.

Shares close at $101.01, up 0.4% on the day, sitting above both the 50-day average of $100.28 and the 200-day average of $92.42. The GekkoIndex reads 51.4, placing the stock in the Neutral zone. Price remains 34.1% below Gekko Fair Value of $153.3.

The next earnings date is set for 25 February 2027, 102 days away, placing it outside a typical 20-trading-day holding period. Current data shows no insider, Congress or unusual options activity in the recent windows, and no billionaire holders recorded, with trailblazer holders at 0. Analyst coverage stands at three firms, all rated hold, with a consensus target of $106.99. Seasonality from this point in the calendar has averaged a 4.9% gain over the next 20 trading days across 5 years, rising in 2 of them.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Lantheus price vs fair value

▲$172.19$101.59Nov ’25May ’26Nov ’26
Close $101.59200-day averageGekko Fair Value $172.19

Lantheus quick facts

Market cap
$6.64B
P/E ratio
25.3
Forward P/E
14.5
EPS, TTM
$4.02
Revenue, TTM
$1.56B
Profit margin
17.3%
Dividend yield
—
Beta
0.03
Volume
758,036 avg 1.07M
1-year return
+86.4%
Typical daily move
±0.5%
Typical 20-day move
±8.9%
50-day average
$100.32
200-day average
$93.11
Next earnings
Feb 25 before open
Shares outstanding
65.40M
52-week range
$51.47$111.86

Lantheus swing-trade checklist

Lantheus scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $101.59 is above the 50-day ($100.32) and 200-day ($93.11) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    48.9, Neutral

    Reading 48.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    41.0% below

    Price is 41% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 102 days

    Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +7.5% on average

    From this point in the calendar, the next 20 trading days averaged +7.5% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Lantheus stock chart and price history

Lantheus closed at $101.59 on Nov 13, 2026, +86.4% over the past year, inside a 52-week range of $51.47 to $111.86.

Close50-day average200-day averageVolume
Lantheus share price, past year, with 50-day and 200-day moving averages and volume$60$80DecJan 2026FebMarAprMayJunJulAugSepOctNov101.59

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+1.6%
3 months
+0.7%
6 months
+8.2%
1 year
+86.4%
The full LNTH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open LNTH in Gekko

Follow Lantheus through every session

Put LNTH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track LNTH in GekkoFree for 7 days. No credit card required.

About Lantheus

Lantheus develops, manufactures and sells diagnostic and therapeutic agents used by clinicians to identify and treat conditions such as heart disease and cancer. Its diagnostic lineup includes DEFINITY for cardiac ultrasound imaging, TechneLite and Cardiolite for nuclear medicine, Xenon-133 for lung function testing, Neurolite for locating stroke damage, Thallium-201 for cardiovascular detection, Gallium-67 for spotting infection and tumors, and PYLARIFY, used to find recurrent or spreading prostate cancer. It is also associated with the Automated Bone Scan Index for measuring prostate cancer in bone scans.

Beyond diagnostics, the company markets AZEDRA, a radiopharmaceutical therapy for adult and pediatric patients, and RELISTOR, used for opioid-induced constipation. Its pipeline covers agents still in development, including flurpiridaz F 18 for blood flow assessment, 1095 and LMI 1195 for tumor targeting, PYLARIFY AI software for analyzing prostate cancer scans, and leronlimab, an antibody under investigation. Customers include radiopharmacies, distributors, hospitals, clinics, integrated delivery networks and group practices, and the company works with partners such as GE Healthcare, Bayer, Curium, FUJIFILM and Regeneron, among others.

Lantheus was established in 1956 and is headquartered in North Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker LNTH.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
lantheus.com

Lantheus GekkoIndex: the smart money zone

Lantheus’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.9, in the Neutral zone, down 4.3 points over five sessions.

010048.9Neutral

Down 4.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying39−0.4%+3.6%+5.1%+3.4%
Accumulation196+0.9%+1.3%+3.9%+3.1%
Neutral (current zone)422+0.8%+1.4%+2.5%+6.9%
Distribution37+0.9%+1.6%+0.4%+18.4%
Selling8Too few readings yet

Average LNTH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the LNTH price, zone by zone.Track LNTH in Gekko

Is Lantheus stock overvalued? Gekko Fair Value

Lantheus trades 41.0% below Gekko Fair Value of $172.19, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Lantheus shares are worth, recalculated every trading day.

$172.19

Gekko Fair Value, Nov 14, 2026

41.0% Undervalued

At the end of Aug 2026 the price was 4.7% below the estimate.

Gekko Fair ValueShare price, month end
$172$102Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open LNTH in Gekko

Lantheus insider and Congress trading

No open-market insider purchases were filed for Lantheus, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for LNTH in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every LNTH insider filing, plotted on the chart in Gekko.Open LNTH in Gekko

Congress trades last 90 days

No trades in LNTH were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for LNTH, plotted on the chart in Gekko.Open LNTH in Gekko

Buybacks

Lantheus has been buying back its own shares.

Bought back, quarter ended Dec 31, 2025
$100.0M
As a share of market cap
1.51%

From company filings.

Hedge funds and billionaires quarter ended Sep 30

0of the funds Gekko tracks hold LNTH.

0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

Lantheus earnings: next date and track record

Lantheus reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±13.2%average move across the report
2 of 8reports followed by a gain

Share-price move across each report

−23.2%Nov ’24+14.3%Feb ’25−23.3%May ’25−24.5%Aug ’25−10.8%Nov ’25−1.1%Feb ’26+8.0%May ’26−0.5%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 6, 2026$1.55
est $1.30
+19.2%$388.2M
est $363.2M
+6.9%−0.5%
May 7, 2026$1.46
est $1.25
+16.8%$377.3M
est $354.5M
+6.4%+8.0%
Feb 26, 2026$1.67
est $1.18
+41.5%$406.8M
est $367.0M
+10.8%−1.1%
Nov 6, 2025$1.27
est $1.27
0.0%$384.0M
est $368.0M
+4.4%−10.8%
Aug 6, 2025$1.57
est $1.64
−4.3%$378.0M
est $363.3M
+4.0%−24.5%
May 7, 2025$1.53
est $1.68
−8.9%$372.8M
est $395.2M
−5.7%−23.3%
Feb 26, 2025$1.59
est $1.58
+0.6%$391.1M
est $379.5M
+3.1%+14.3%
Nov 6, 2024$1.70
est $1.56
+9.0%$378.7M
est $375.9M
+0.8%−23.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Lantheus stock forecast and analyst price targets

Analysts’ average 12-month price target for Lantheus is $105.99, +4.3% from the last close, from 2 firms rating the stock in the last 90 days.

$105.99consensus 12-month target, +4.3% from the last close
Low $105.40High $109
Buy0
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 2 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 13Mizuho SecuritiesHold, downgraded$109+7.3%
Aug 17B. Riley SecuritiesHold, downgraded$105.40+3.8%
+2.5%average 20-day move after past Neutral readings
+7.5%average move over the next 20 trading days in the last 5 years
±0.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Lantheus seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Lantheus averaged +7.5% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−10.8%2021−4.7%2022+12.0%2023+15.1%2024+25.6%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+2.2%3 of 5
Next 10 trading days+4.6%4 of 5
Next 15 trading days+5.2%3 of 5
Next 20 trading days+7.5%3 of 5
Next 30 trading days+3.8%3 of 5

For scale, LNTH’s typical 20-trading-day move in either direction is about 8.9%.

Lantheus market cap and key statistics

Lantheus’s market cap is $6.64B, with a P/E ratio of 25.3 and revenue of $1.56B over the last twelve months.

Valuation

Market cap
$6.64B
P/E ratio
25.3
Forward P/E
14.5
EPS, TTM
$4.02
Gekko Fair Value
$172.19

Trading

Volume
758,036
Avg volume, 20 days
1.07M
52-week high
$111.86
52-week low
$51.47
Shares outstanding
65.40M

Financials

Revenue, TTM
$1.56B
Profit margin
17.3%
Return on equity
21.8%
Quarterly earnings growth, YoY
−19.5%

Risk and income

Beta
0.03
Typical daily move
±0.5%
Typical 20-day move
±8.9%

Lantheus peers

Lantheus’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Lantheus stock FAQ

What is Lantheus’s market cap?

Lantheus’s market cap is $6.64B at the Nov 13, 2026 close of $101.59, with 65.40M shares outstanding. The shares trade on a P/E ratio of 25.3.

What is the Lantheus stock forecast?

The consensus analyst 12-month price target for Lantheus is $105.99, +4.3% from the last close. Of the 2 firms that rated the stock in the last 90 days, 0 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Lantheus stock overvalued or undervalued?

On Gekko’s estimate Lantheus is undervalued: the Nov 13, 2026 close of $101.59 is 41.0% below Gekko Fair Value of $172.19. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Lantheus report earnings next?

Lantheus is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of $1.31 per share on revenue of $373.3M. Lantheus beat the earnings estimate in 5 of its last 8 reports, moving 13.2% on average across the report.

What is Lantheus’s 52-week high and low?

Lantheus’s 52-week high is $111.86 and its 52-week low is $51.47; it closed at $101.59 on Nov 13, 2026, +86.4% over the past year. Over the last five years the shares peaked at $126.89 on Jul 16, 2024.

Is Lantheus stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Lantheus the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.